Abstract
Assessing patient eligibility for hematopoietic stem cell transplantation (HSCT) remains a complex, multifaceted challenge. Among these challenges, the paucity of comprehensive clinical data to guide decision making remains problematic coupled with unclear trade-offs between patient, disease and local HSCT center factors. Moreover, it is unclear that the modification of poor patient characteristics will improve post-HSCT outcomes. However, the use of Comorbidity Indices and Comprehensive Geriatric Assessments helps meet this challenge, but may be limited by overlapping patient characteristics. The increasing consideration for pre-HSCT psychosocial assessments and interventions remains to be studied. Ultimately, the decision to proceed with a HSCT remains interdisciplinary while considering the available evidence discussed in this review.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hamadani M, Craig M, Awan FT, Devine SM. How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45:1259–68. https://doi.org/10.1038/bmt.2010.94
Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25:1993–9. https://doi.org/10.1200/JCO.2006.09.0100
Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600–7.
Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51–54.
Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol. 2008;83:614–7. https://doi.org/10.1002/ajh.21191
Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, et al. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014;20:1796–803. https://doi.org/10.1016/j.bbmt.2014.07.013
Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RR, Ruan J, et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012;87:433–5. https://doi.org/10.1002/ajh.23108
Martin N, Borchiellini D, Coso D, Gastaud L, Boscagli A, Saudes L, et al. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leuk Lymphoma. 2015;56:2379–87. https://doi.org/10.3109/10428194.2014.1001987
Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014;20:684–9. https://doi.org/10.1016/j.bbmt.2014.01.025
D’Souza A, Zhu X. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR Summary Slides, 2016. https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx
Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28:405–11. https://doi.org/10.1200/JCO.2009.21.8073
McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878–87. https://doi.org/10.1200/JCO.2009.25.4821
Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306:1874–83. https://doi.org/10.1001/jama.2011.1558
Russell JA, Irish W, Balogh A, Chaudhry MA, Savoie ML, Turner AR, et al. The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant. 2010;16:509–14. https://doi.org/10.1016/j.bbmt.2009.11.017
Rosko A, Artz A. Aging: treating the older patient. Biol Blood Marrow Transplant. 2017;23:193–200. https://doi.org/10.1016/j.bbmt.2016.11.007
Muffly LS, Boulukos M, Swanson K, Kocherginsky M, Cerro PD, Schroeder L, et al. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant. 2013;19:429–34. https://doi.org/10.1016/j.bbmt.2012.11.006
Holmes HM, Des Bordes JK, Kebriaei P, Yennu S, Champlin RE, Giralt S, et al. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. J Geriatr Oncol. 2014;5:422–30. https://doi.org/10.1016/j.jgo.2014.04.004
Melzer D, Frayling TM, Murray A, Hurst AJ, Harries LW, Song H, et al. A common variant of thep16(INK4a) genetic region is associated with physical function in older people. Mech Ageing Dev. 2007;128:370–7. https://doi.org/10.1016/j.mad.2007.03.005
Liu Y,Sanoff HK,Cho H,Burd CE,Torrice C,Ibrahim JG, et al. Expression ofp16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009;8:439–48.
Lagro J, Studenski SA, Olde Rikkert MG. Predicting chemotherapy toxicity in older adults and the importance of geriatric assessment. J Clin Oncol. 2012;30:560 https://doi.org/10.1200/JCO.2011.39.4858. author reply 561-562
Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. Leuk Res. 2014;38:275–83. https://doi.org/10.1016/j.leukres.2013.12.018
Hurria A, Wildes T, Blair SL, Browner IS, Cohen HJ, Deshazo M, et al. Senior adult oncology, version 2.2014: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014;12:82–126.
Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99:1373–9. https://doi.org/10.3324/haematol.2014.103655
Deschler B, Ihorst G, Schnitzler S, Bertz H, Finke J. Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. Bone Marrow Transplant. 2018;53:565–75. https://doi.org/10.1038/s41409-017-0021-4
Hegde A, Murthy HS. Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment? Bone Marrow Transplant. 2018;53:3–10. https://doi.org/10.1038/bmt.2017.192
Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:223–9.
Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:1261–9. https://doi.org/10.1016/j.bbmt.2006.07.016
Chien JW, Sullivan KM. Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility? Biol Blood Marrow Transplant. 2009;15:447–53. https://doi.org/10.1016/j.bbmt.2008.12.509
Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med. 2006;144:407–14.
El-Khatib M, Bou-Khalil P, Abbas O, Salman A, Jamaleddine G. Value of pretransplant pulmonary function tests in predicting pulmonary complications after autologous peripheral stem cell transplantation. Lung. 2007;185:321–4. https://doi.org/10.1007/s00408-007-9047-5
Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1072–8. https://doi.org/10.1016/j.bbmt.2010.11.018
Coghlan JG, Handler CE, Kottaridis PD. Cardiac assessment of patients for haematopoietic stem cell transplantation. Best Pract Res Clin Haematol. 2007;20:247–63. https://doi.org/10.1016/j.beha.2006.09.005
Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant. 2001;28:283–7. https://doi.org/10.1038/sj.bmt.1703133
Hurley P, Konety S, Cao Q, Weisdorf D, Blaes A. Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done? Biol Blood Marrow Transplant. 2015;21:300–4. https://doi.org/10.1016/j.bbmt.2014.10.011
Nakamae H, Hino M, Akahori M, Terada Y, Yamane T, Ohta K, et al. Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2004;76:1–7. https://doi.org/10.1002/ajh.20042
McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–67.
Armand P, Kim HT, Virtanen JM, Parkkola RK, Itala-Remes MA, Majhail NS, et al. Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant. 2014;20:1248–51. https://doi.org/10.1016/j.bbmt.2014.04.024
Ramos CA, Saliba RM, de Padua L, Khorshid O, Shpall EJ, Giralt S, et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica. 2009;94:249–57. https://doi.org/10.3324/haematol.13756
Colecchia A, Marasco G, Ravaioli F, Kleinschmidt K, Masetti R, Prete A, et al. Usefulness of liver stiffness measurement in predicting hepatic veno-occlusive disease development in patients who undergo HSCT. Bone Marrow Transplant. 2017;52:494–7. https://doi.org/10.1038/bmt.2016.320
Lau JE, Weber C, Earl M, Rybicki LA, Carlstrom KD, Wenzell CM, et al. Outcomes after autologous SCT in lymphoma patients grouped by weight. Bone Marrow Transplant. 2015;50:652–7. https://doi.org/10.1038/bmt.2014.327
Gleimer M, Li Y, Chang L, Paczesny S, Hanauer DA, Frame DG, et al. Baseline body mass index among children and adults undergoing allogeneic hematopoietic cell transplantation: clinical characteristics and outcomes. Bone Marrow Transplant. 2015;50:402–10. https://doi.org/10.1038/bmt.2014.280
Baumgartner A, Zueger N, Bargetzi A, Medinger M, Passweg JR, Stanga Z, et al. Association of nutritional parameters with clinical outcomes in patients with acute myeloid leukemia undergoing haematopoietic stem cell transplantation. Ann Nutr Metab. 2016;69:89–98. https://doi.org/10.1159/000449451
Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P. Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant. 2016;51:1337–41. https://doi.org/10.1038/bmt.2016.136
Ataei S, Hadjibabaie M, Moslehi A, Taghizadeh-Ghehi M, Ashouri A, Amini E, et al. A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2015;33:67–74. https://doi.org/10.1002/hon.2141
Oshima K, Kanda Y, Nanya Y, Tanaka M, Nakaseko C, Yano S, et al. Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatinine clearance before transplantation. Ann Hematol. 2013;92:255–60. https://doi.org/10.1007/s00277-012-1584-1
Shimoi T, Ando M, Munakata W, Kobayashi T, Kakihana K, Ohashi K, et al. The significant impact of acute kidney injury on CKD in patients who survived over 10 years after myeloablative allogeneic SCT. Bone Marrow Transplant. 2013;48:80–84. https://doi.org/10.1038/bmt.2012.85
Kagoya Y, Kataoka K, Nannya Y, Kurokawa M. Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:394–400. https://doi.org/10.1016/j.bbmt.2010.07.010
Melkos AB, Massenkeil G, Arnold R, Reichart PA. Dental treatment prior to stem cell transplantation and its influence on the posttransplantation outcome. Clin Oral Investig. 2003;7:113–5. https://doi.org/10.1007/s00784-003-0209-4
Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;27:387–404.
Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12:954–64. https://doi.org/10.1016/j.bbmt.2006.05.015
Au BK, Gooley TA, Armand P, Fang M, Madtes DK, Sorror ML, et al. Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2015;21:848–54. https://doi.org/10.1016/j.bbmt.2015.01.011
Mori Y, Teshima T, Kamezaki K, Kato K, Takenaka K, Iwasaki H, et al. Validation of pretransplantation assessment of mortality risk score in the outcome of hematopoietic SCT in non-Caucasians. Bone Marrow Transplant. 2012;47:1075–81. https://doi.org/10.1038/bmt.2011.229
Kishore BW, Nikolousis D, Lovell E, Milligan R, Holder D, Bratby K, Murthy L, Paneesha V. Pre-transplantation assessment of mortality (PAM) score is a poor predictor for survival in the highest risk group when used in T cell depleted myeloablative allogeneic transplants. Blood. 2013;122:5553. http://www.bloodjournal.org/content/122/21/5553
Wiseman D, Nikolousis E, Lovell R, Milligan D, Holder K, Bratby L, et al. Pre-transplantation assessment of mortality (PAM) score is a poor predictor for survival in the highest risk group when used In T cell depleted myeloablative allogeneic transplants. Blood. 2013;122:5553–5553.
Labonte L, Iqbal T, Zaidi MA, McDiarmid SA, Huebsch LB, Tay J, et al. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2008;14:1039–44. https://doi.org/10.1016/j.bbmt.2008.06.019
Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47:749–56. https://doi.org/10.1038/bmt.2011.110
Lozano SO,E, Iacobelli S, van Biezen A, Beelen D, Finke J, Mufti G, et al. The EBMT score predicts transplant related mortality and overall survival after allogeneic stem cell transplantation for myelodysplastic syndromes. Blood. 2015;126:3223. http://www.bloodjournal.org/content/126/23/3223
Gul Z, Khan H, Bashir Q, Shah N, Parmar S, Dinh YT, et al. EBMT risk score for pre transplant risk assessment in patients with multiple myeloma. Blood. 2012;120:3094–3094.
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9. https://doi.org/10.1182/blood-2005-05-2004
Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992–2001. https://doi.org/10.1002/cncr.23375
Michelis FV, Messner HA, Atenafu EG, McGillis L, Lambie A, Uhm J, et al. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. Bone Marrow Transplant. 2015;50:1405–10. https://doi.org/10.1038/bmt.2015.165
Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, Craddock C, et al. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant. 2012;47:528–34. https://doi.org/10.1038/bmt.2011.138
Nakaya A, Mori T, Tanaka M, Tomita N, Nakaseko C, Yano S, et al. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy. Biol Blood Marrow Transplant. 2014;20:1553–9. https://doi.org/10.1016/j.bbmt.2014.06.005
Mo XD, Xu LP, Liu DH, Zhang XH, Chen H, Chen YH, et al. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol. 2013;88:497–502. https://doi.org/10.1002/ajh.23443
Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, et al. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. Bone Marrow Transplant. 2014;49:1323–9. https://doi.org/10.1038/bmt.2014.155
Berro M,Rivas MM,Arbelbide JA,Basquiera AL,Vitriu A,Foncuberta MC, et al. HCT.CI in autologous stem cell transplantation. Predicting early and late transplant related mortality. Blood. 2016;128:3449
Kassar M, Gregory SA, Shell K, Venugopal P, Shammo J, Farhat MI, et al. Assessing the impact of comorbidities on autologous hematopoietic cell transplant (AHCT) outcomes using the hematopoietic cell transplant-comorbidity index (HCT-CI) in lymphoma. J Clin Oncol. 2007;25(18_suppl):7102–7102. https://doi.org/10.1200/jco.2007.25.18_suppl.7102
Michelis FV,Messner HA,Uhm J,Lambie A,McGillis L,Gupta V, et al. The modified pre-transplant EBMT risk score is superior to the HCT-CI score in predicting overall survival and non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Blood. 2013;122:2153
Terwey TH, Hemmati PG, Martus P, Dietz E, Vuong LG, Massenkeil G, et al. A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Haematologica. 2010;95:810–8. https://doi.org/10.3324/haematol.2009.011809
Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20:402–8 e401. https://doi.org/10.1016/j.bbmt.2013.12.557
Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H. Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation. Am J Hematol. 2014;89:E138–141. https://doi.org/10.1002/ajh.23764
Foster LW, McLellan LJ, Rybicki LA, Dabney J, Welsh E, Bolwell BJ. Allogeneic BMT and patient eligibility based on psychosocial criteria: a survey of BMT professionals. Bone Marrow Transplant. 2006;37:223–8. https://doi.org/10.1038/sj.bmt.1705219
Foster LW, McLellan L, Rybicki L, Tyler T, Bolwell BJ. Ethical reasoning about patient eligibility in allogeneic BMT based on psychosocial criteria. Bone Marrow Transplant. 2009;44:607–12. https://doi.org/10.1038/bmt.2009.58
Bevans M, Wehrlen L, Prachenko O, Soeken K, Zabora J, Wallen GR. Distress screening in allogeneic hematopoietic stem cell (HSCT) caregivers and patients. Psychooncology. 2011;20:615–22. https://doi.org/10.1002/pon.1906
Bultz BD, Groff SL, Fitch M, Blais MC, Howes J, Levy K, et al. Implementing screening for distress, the 6th vital sign: a Canadian strategy for changing practice. Psychooncology. 2011;20:463–9. https://doi.org/10.1002/pon.1932
Giese-Davis J, Waller A, Carlson LE, Groff S, Zhong L, Neri E, et al. Screening for distress, the 6th vital sign: common problems in cancer outpatients over one year in usual care: associations with marital status, sex, and age. BMC Cancer. 2012;12:441 https://doi.org/10.1186/1471-2407-12-441
Garcia C Jr, Botega NJ, De Souza CA. A psychosocial assessment interview of candidates for hematopoietic stem cell transplantation. Haematologica. 2005;90:570–2.
Foster LW, McLellan L, Rybicki L, Dabney J, Visnosky M, Bolwell B. Utility of the psychosocial assessment of candidates for transplantation (PACT) scale in allogeneic BMT. Bone Marrow Transplant. 2009;44:375–80. https://doi.org/10.1038/bmt.2009.37
Olbrisch MEL, J L, Hamer R. ThePACT: a rating scale for the study of clinical decision-making in psychosocial screening of organ transplant candidates. Clin Transplant. 1989;3:164–9.
Hong S, Rybicki L, Abounader D, Dabney J, Dean RM, Gerds AT, et al. Pre-transplant psychosocial assessment and outcomes of allogeneic hematopoietic cell transplantation in adults. Blood. 2016;128:3552–3552.
Hoodin F, Zhao L, Carey J, Levine JE, Kitko C. Impact of psychological screening on routine outpatient care of hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2013;19:1493–7. https://doi.org/10.1016/j.bbmt.2013.07.019
Kuba K, Esser P, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A, et al. Cancer-and-treatment-specific distress and its impact on posttraumatic stress in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Psychooncology. 2016;26:1164–71. https://doi.org/10.1002/pon.4295
Ehrlich KB, Miller GE, Scheide T, Baveja S, Weiland R, Galvin J, et al. Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:1594–8. https://doi.org/10.1038/bmt.2016.191
Baliousis M, Rennoldson M, Snowden JA. Psychological interventions for distress in adults undergoing haematopoietic stem cell transplantation: a systematic review with meta-analysis. Psychooncology. 2016;25:400–11. https://doi.org/10.1002/pon.3925
Kuba K, Esser P, Mehnert A, Johansen C, Schwinn A, Schirmer L, et al. Depression and anxiety following hematopoietic stem cell transplantation: a prospective population-based study in Germany. Bone Marrow Transplant. 2017;52:1651–7. https://doi.org/10.1038/bmt.2017.190
El-Jawahri A, Chen YB, Brazauskas R, He N, Lee SJ, Knight JM, et al. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer. 2017;123:1828–38. https://doi.org/10.1002/cncr.30546
Haynes RT, D W, Sackett DL. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979. p. 1–2.
Bishop MM, Rodrigue JR, Wingard JR. Mismanaging the gift of life: noncompliance in the context of adult stem cell transplantation. Bone Marrow Transplant. 2002;29:875–80. https://doi.org/10.1038/sj.bmt.1703523
Mumby PB, Hurley C, Samsi M, Thilges S, Parthasarathy M, Stiff PJ. Predictors of non-compliance in autologous hematopoietic SCT patients undergoing out-patient transplants. Bone Marrow Transplant. 2012;47:556–61. https://doi.org/10.1038/bmt.2011.129
Rodrigue JR, Pearman TP, Moreb J. Morbidity and mortality following bone marrow transplantation: predictive utility of pre-BMT affective functioning, compliance, and social support stability. Int J Behav Med. 1999;6:241–54. https://doi.org/10.1207/s15327558ijbm0603_3
Stagno S, Busby K, Shapiro A, Kotz M. Patients at risk: addressing addiction in patients undergoing hematopoietic SCT. Bone Marrow Transplant. 2008;42:221–6. https://doi.org/10.1038/bmt.2008.211
Chang G, Antin JH, Orav EJ, Randall U, McGarigle C, Behr HM. Substance abuse and bone marrow transplant. Am J Drug Alcohol Abus. 1997;23:301–8.
Chang G, Orav EJ, Tong MY, Antin JH. Predictors of 1-year survival assessed at the time of bone marrow transplantation. Psychosomatics. 2004;45:378–85. https://doi.org/10.1176/appi.psy.45.5.378
Turcotte LM, Verneris MR. Is it better to be rich or relaxed? Sociobiology meets bone marrow transplant. Clin Cancer Res. 2016;22:6–8. https://doi.org/10.1158/1078-0432.CCR-15-2112
Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, et al. Patient-reported outcomes and socioeconomic status as predictors of clinical outcomes after hematopoietic stem cell transplantation: a study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. Biol Blood Marrow Transplant. 2016;22:2256–63. https://doi.org/10.1016/j.bbmt.2016.08.016
Fu S, Rybicki L, Abounader D, Andresen S, Bolwell BJ, Dean R, et al. Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50:1326–30. https://doi.org/10.1038/bmt.2015.166
Silla L, Fischer GB, Paz A, Daudt LE, Mitto I, Katz B, et al. Patient socioeconomic status as a prognostic factor for allo-SCT. Bone Marrow Transplant. 2009;43:571–7. https://doi.org/10.1038/bmt.2008.358
Hong S, Rybicki L, Abounader D, Bolwell BJ, Dean R, Gerds AT, et al. Association of socioeconomic status with outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2016;22:1141–4. https://doi.org/10.1016/j.bbmt.2016.03.011
Frick E, Motzke C, Fischer N, Busch R, Bumeder I. Is perceived social support a predictor of survival for patients undergoing autologous peripheral blood stem cell transplantation? Psychooncology. 2005;14:759–70. https://doi.org/10.1002/pon.908
Beattie S, Lebel S, Petricone-Westwood D, Wilson KG, Harris C, Devins G, et al. Balancing give and take between patients and their spousal caregivers in hematopoietic stem cell transplantation. Psychooncology. 2016;26:2224–31. https://doi.org/10.1002/pon.4340
Beattie S, Lebel S, Tay J. The influence of social support on hematopoietic stem cell transplantation survival: a systematic review of literature. PLoS ONE. 2013;8:e61586 https://doi.org/10.1371/journal.pone.0061586
Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhauser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9:579–90. https://doi.org/10.1038/nrclinonc.2012.150
Marsh K, IJzerman M, Thokala P, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making--emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19:125–37. https://doi.org/10.1016/j.jval.2015.12.016
Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making--an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19:1–13. https://doi.org/10.1016/j.jval.2015.12.003
Guler S, Hurton S, Cwinn M, Molinari M. Levels in decision making and techniques for clinicians. Glob J Dig Dis. 2015;1:1–11. https://doi.org/10.4172/2472-1891.100002
Norris S, Shendale S. Decision-making for guideline development at WHO. In: WHO handbook for guideline development, 2nd ed. World Health Organization; 2014, p. 201-14. http://www.who.int/publications/guidelines/Chp16_May2016.pdf, http://www.who.int/publications/guidelines/handbook_2nd_ed.pdf
Institute OHR. Patient Decision Aids. 2015. https://decisionaid.ohri.ca/
Drug and Therapeutics Bulletin. An introduction to patient decision aids. BMJ. 2013;347:f4147 https://doi.org/10.1136/bmj.f4147
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Tay, J., Daly, A., Jamani, K. et al. Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables. Bone Marrow Transplant 54, 368–382 (2019). https://doi.org/10.1038/s41409-018-0265-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0265-7
This article is cited by
-
Worked to the bone: antibody-based conditioning as the future of transplant biology
Journal of Hematology & Oncology (2022)
-
Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies
Current Oncology Reports (2022)